Aurobindo Pharma Limited has informed the Exchange regarding a press release dated April 09, 2025, titled "CuraTeQ Biologics completes a successful Phase 1 Pharmacokinetics study of Denosumab BP16, a proposed biosimilar to Prolia? and Xgeva?".
Press Release Apr 09 2025
Filed with NSE ·
6ix hasn’t read this filing yet.
Earlier from Aurobindo Pharma
- Press Release Feb 06 2025
- Press Release Jan 31 2025
- Press Release Dec 21 2024
- Press Release Dec 13 2024
- Press Release Dec 05 2024
Later from Aurobindo Pharma
- Press Release Apr 12 2025
- Press Release Apr 23 2025
- Press Release Apr 26 2025
- Press Release May 13 2025
- Press Release May 26 2025
Follow Aurobindo Pharma into a list and get an email when it puts out news.
Follow Aurobindo Pharma